Keuangan Abbott Laboratories (ABT)
NYSE · Healthcare · Medical - Devices · Karyawan: 115.000 · CEO: Robert Ford
- Harga
- $106,20 +1,56%
- Kapitalisasi pasar
- $184 M
- Nilai perusahaan
- $211 M
- Laporan terakhir
- Q3 '26 diajukan 2026-09-30
- Laporan berikutnya
- 2027-01-28 Estimasi EPS: $1,64
Pendapatan (TTM)$48,2 M+10,0% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)15,2%-2,5 poin vs tahun laluLaba operasional: $7,35 M
Laba bersih (TTM)$4,7 M-66,4% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)–– vs tahun laluCapex: –
EPS dilusian (TTM)$2,70-66,2% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$27 M-338,7% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $184 M EV $211 M
- Pendapatan
- $48,2 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +13% Konsensus FY2026
- Margin laba
- 9,7% Laba bersih / pendapatan, TTM
- P/E
- 39,3× Forward 19,2× (FY2026)
- P/S
- 3,8× Harga / penjualan, TTM
- EV / EBITDA
- 21,8× TTM
- Arus kas bebas
- – 12 bulan terakhir
- Laba bersih
- $4,7 M 12 bulan terakhir
- Estimasi pendapatan
- $50 M Konsensus FY2026
- Laba
- 2027-01-28 Estimasi pendapatan: $13,2 M
- Dividen
- $2,52 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-21): pendapatan sesuai ekspektasi, EPS sesuai ekspektasiPendapatan $13 M vs $13 M yang diharapkan (+0,2%); EPS $1,42 vs $1,42 (0,0%).
- Pertumbuhan pendapatan menguat: 14,5% yoyPendapatan Q3 '26: $13 M, rata-rata empat kuartal sebelumnya: 8,0%.
- Margin operasional 15,2% (TTM), dibanding tahun lalu: -2,5 poinLaba operasional tumbuh -5,6%, pendapatan tumbuh 10,0%.
- 12,0% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $6,56 M vs laba operasional $7,35 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Jumlah saham dilusian turun dalam setahun: 0,6%Saham dilusian pada Q3 '26: 1,74 M, setahun sebelumnya: 1,75 M.
- Utang neto: $27 MKas + investasi jangka pendek: $5,6 M, utang termasuk sewa: $32,6 M; tahun lalu utang neto: $6,16 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $13 M | $11,4 M | +14,5% |
| Margin kotor | 57,1% | 55,7% | +1,3 poin |
| Laba operasional | $1,48 M | $2,06 M | -28,2% |
| Margin operasional | 11,3% | 18,1% | -6,8 poin |
| Laba bersih | $920 jt | $1,64 M | -44,0% |
| EPS dilusian | $0,53 | $0,94 | -43,6% |
| Arus kas operasional | – | $2,79 M | – |
| Capex | – | $496 jt | – |
| Arus kas bebas | – | $2,29 M | – |
| R&D | $908 jt | $785 jt | +15,7% |
| Kompensasi berbasis saham | – | $120 jt | – |
Dilaporkan vs konsensus
2026-10-21| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $13 M | $13 M | +0,2% |
| EPS (basis konsensus) | $1,42 | $1,42 | 0,0% |
Dari laporan 2026-10-21 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Diagnostic Products | $3,09 M | -47,6% | 24,6% | $11,3 M | -12,5% | |
| Medical Devices | $5,85 M | +9,0% | 46,5% | $22,5 M | +12,2% | |
| Nutritional Products | $2,14 M | -3,1% | 17,0% | $8,25 M | -3,5% | |
| Established Pharmaceutical Products | $1,5 M | +8,4% | 11,9% | – | – | |
| Established Pharmaceuticals | – | – | – | – | – | |
| Other | $5 jt | – | 0,0% | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Non-US | $7,38 M | +7,4% | 58,6% | $21,3 M | -18,3% | |
| United States | $5,22 M | +22,0% | 41,4% | $18,2 M | +7,0% |
Laba segmen
Laba operasional per segmen pelaporan, dibaca dari catatan segmen setiap 10-Q / 10-K (rincian laba yang tidak ada di sebagian besar data feed).
Segmen pada Q2 '26
| Segmen | Pendapatan | yoy | Laba operasional | yoy | Margin | Margin tahun lalu | Laba operasional TTM |
|---|---|---|---|---|---|---|---|
| Established Pharmaceutical Products | – | – | $382 jt | +10,4% | – | – | $1,39 M |
| Nutritional Products | – | – | $368 jt | -12,0% | – | – | $1,43 M |
| Diagnostic Products | – | – | $499 jt | +34,1% | – | – | $1,84 M |
| Medical Devices | – | – | $1,97 M | +9,6% | – | – | $7,67 M |
Laba operasional per segmen
kuartalanMargin operasional segmen
kuartalanKuartal keempat dihitung: 10-K melaporkan setahun penuh, dikurangi tiga kuartal dari 10-Q.
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas bebas
- –
- Dikembalikan ke pemegang saham / FCF
- –
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 39,3× | 29,0× | 14,7× – 35,5× |
| EV / EBITDA | 21,8× | 18,9× | 16,9× – 21,3× |
| EV / Penjualan | 4,4× | 5,1× | 4,6× – 6,0× |
| Harga / FCF | 21,1× | 30,3× | 24,7× – 37,7× |
| Harga / Nilai buku | 3,6× | 5,1× | 4,1× – 7,0× |
| Imbal hasil FCF | 4,7% | 3,4% | 2,7% – 4,1% |
| Imbal hasil modal yang diinvestasikan | 5,6% | 10,3% | 8,4% – 12,6% |
| Imbal hasil ekuitas | 9,1% | 18,8% | 12,5% – 28,1% |
Analis
Target konsensus $121,36 (+14,3%)
rentang $112,00 – $130,00 · peringkat Buy
Beli kuat0
Beli33
Tahan10
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $50 M | +12,8% | $5,52 | +48,3% | 19,2× | 17 |
| FY2027 | $53,7 M | +7,4% | $5,93 | +7,6% | 17,9× | 18 |
| FY2028 | $57,1 M | +6,5% | $6,50 | +9,5% | 16,3× | 14 |
| FY2029 | $61,4 M | +7,5% | $7,21 | +10,8% | 14,7× | 7 |
| FY2030 | $65,8 M | +7,1% | $7,94 | +10,2% | 13,4× | 11 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 232 angka yang ditandai Abbott Laboratories dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Trade, Current | $4,68 M | $4,21 M | +11,0% | $4,24 M | $4,2 M | +1,1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $8,21 M | $7,33 M | +12,1% | $7,93 M | $6,93 M | +14,5% |
| Accounts Receivable, Allowance for Credit Loss | $310 jt | $259 jt | +19,7% | $290 jt | $247 jt | +17,4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $494 jt | $449 jt | +10,0% | $490 jt | $439 jt | +11,6% |
| Accounts Receivable, Allowance for Credit Loss, Writeoff | $6 jt | $11 jt | -45,5% | $32 jt | $55 jt | -41,8% |
| Accounts Receivable, Credit Loss Expense (Reversal) | $26 jt | $23 jt | +13,0% | $75 jt | $61 jt | +23,0% |
| Accrued Income Taxes, Current | $598 jt | $485 jt | +23,3% | $569 jt | $594 jt | -4,2% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $13,4 M | $12,5 M | +7,0% | $13,4 M | $12,1 M | +11,0% |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | $14 jt | $581 jt | -97,6% | $1 jt | $611 jt | -99,8% |
| Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | -$6,33 M | -$6,96 M | +9,0% | -$5,93 M | -$7,51 M | +21,0% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$6,31 M | -$7,42 M | +14,9% | -$6 M | -$7,91 M | +24,1% |
| Amortization of Intangible Assets | $422 jt | $420 jt | +0,5% | $1,68 M | $1,88 M | -10,4% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 9,9 jt | 1,43 jt | +591,8% | 1 jt | 7 jt | -85,7% |
| AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax | $33 jt | $119 jt | -72,3% | -$69 jt | $210 jt | -132,9% |
| Assets | $110 M | $81,4 M | +35,6% | $86,7 M | $81,4 M | +6,5% |
| Assets, Current | $25,5 M | $23,2 M | +10,2% | $26 M | $23,7 M | +9,9% |
| Assets, Fair Value Disclosure | $575 jt | – | – | $450 jt | $714 jt | -37,0% |
| Buildings and Improvements, Gross | $4,54 M2025-12-31 | $4,21 M | +8,0% | $4,54 M | $4,21 M | +8,0% |
| Business Combination, Contingent Consideration, Liability | $304 jt | – | – | $1 jt | $38 jt | -97,4% |
| Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $96 jt | – | – | – | – | – |
| Cash and Cash Equivalents, at Carrying Value | $6,8 M | $6,53 M | +4,1% | $8,52 M | $7,62 M | +11,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $6,8 M | $6,53 M | +4,1% | $8,52 M | $7,62 M | +11,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$1,72 M | -$1,08 M | -58,6% | $906 jt | $720 jt | +25,8% |
| Common Stock, Dividends, Per Share, Declared | $0,63 | $0,59 | +6,8% | $2,40 | $2,24 | +7,1% |
| Common Stock, Shares Authorized | 2,4 M | 2,4 M | 0,0% | 2,4 M | 2,4 M | 0,0% |
| Common Stock, Shares, Issued | 2 M | 2 M | +0,1% | 2 M | 1,99 M | +0,3% |
| Common Stock, Value, Issued | $25,4 M | $25,1 M | +0,9% | $25,5 M | $25,2 M | +1,5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $766 jt | $1,81 M | -57,8% | $8,43 M | $13,3 M | -36,8% |
| Construction in Progress, Gross | $2,57 M2025-12-31 | $2,49 M | +3,2% | $2,57 M | $2,49 M | +3,2% |
| Contract with Customer, Liability | $660 jt | $601 jt | +9,8% | $633 jt | $568 jt | +11,4% |
| Contract with Customer, Liability, Revenue Recognized | $123 jt | $99 jt | +24,2% | -$423 jt | -$460 jt | +8,0% |
| Cost of Goods and Services Sold | $4,89 M | $4,47 M | +9,4% | $19,3 M | $18,7 M | +3,3% |
| Costs and Expenses | $9,82 M | $8,67 M | +13,3% | $36,3 M | $35,1 M | +3,3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $302 jt | – | – |
| Current Federal, State and Local, Tax Expense (Benefit) | – | – | – | $85 jt | $497 jt | -82,9% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $1,11 M | $1,08 M | +3,6% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,5 M | $1,57 M | -4,5% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $497 jt | -100,0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$217 jt | – | – |
| Deferred Federal, State and Local, Tax Expense (Benefit) | – | – | – | -$40 jt | -$459 jt | +91,3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $698 jt | -$7,5 M | +109,3% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $441 jt | -$7,96 M | +105,5% |
| Deferred Income Taxes and Other Assets, Noncurrent | $18,4 M | $16,8 M | +9,0% | $18,4 M | $16,5 M | +11,9% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | -$459 jt | +100,0% |
| Deferred Tax Assets, Gross | $11,6 M2025-12-31 | $12,1 M | -3,9% | $11,6 M | $12,1 M | -3,9% |
| Deferred Tax Assets, in Process Research and Development | $902 jt2025-12-31 | $773 jt | +16,7% | $902 jt | $773 jt | +16,7% |
| Deferred Tax Assets, Inventory | $146 jt2025-12-31 | $168 jt | -13,1% | $146 jt | $168 jt | -13,1% |
| Deferred Tax Assets, Net | $7,51 M2025-12-31 | $8,11 M | -7,5% | $7,51 M | $8,11 M | -7,5% |
| Deferred Tax Assets, Net of Valuation Allowance | $9,83 M2025-12-31 | $10,4 M | -5,5% | $9,83 M | $10,4 M | -5,5% |
| Deferred Tax Assets, Other | $9,73 M2025-12-31 | $10,4 M | -6,0% | $9,73 M | $10,4 M | -6,0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | $227 jt2025-12-31 | $230 jt | -1,3% | $227 jt | $230 jt | -1,3% |
| Deferred Tax Assets, Valuation Allowance | $1,77 M2025-12-31 | $1,66 M | +6,4% | $1,77 M | $1,66 M | +6,4% |
| Deferred Tax Liabilities, Gross | $2,33 M2025-12-31 | $2,3 M | +1,3% | $2,33 M | $2,3 M | +1,3% |
| Deferred Tax Liabilities, Other | $1,06 M2025-12-31 | $1,37 M | -22,6% | $1,06 M | $1,37 M | -22,6% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $489 jt2025-12-31 | $408 jt | +19,9% | $489 jt | $408 jt | +19,9% |
| Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $1,28 M2025-12-31 | $1,18 M | +8,1% | $1,28 M | $1,18 M | +8,1% |
| Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets | $152 jt2025-12-31 | $149 jt | +2,0% | $152 jt | $149 jt | +2,0% |
| Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $1,28 M2025-12-31 | $1,18 M | +8,1% | $1,28 M | $1,18 M | +8,1% |
| Defined Benefit Plan, Plan Assets, Amount | $16,6 M2025-12-31 | $14,4 M | +15,0% | $16,6 M | $14,4 M | +15,0% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation | $1,2 M2025-12-31 | $1,11 M | +7,6% | $1,2 M | $1,11 M | +7,6% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01